biotech · Fabry Disease (X-linked lysosomal storage disease). · Kidney Transplant Rejection · SGMO
SANGAMO THERAPEUTICS
SANGAMO THERAPEUTICS, INC
SANGAMO THERAPEUTICS clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
7000 Marina Blvd, Brisbane, California 94005, US HQ
1995 Founded
266 Employees
Public company Type
SGMO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 7000 Marina Blvd, Brisbane, California 94005, US
- Founded
- 1995
- Employees
- 266
- Programs
- 25
- Drugs
- 14
- Patents
- 192
SANGAMO THERAPEUTICS projects
1 ClinicalTrials.gov programs sponsored by SANGAMO THERAPEUTICS.
SANGAMO THERAPEUTICS has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
Frequently asked questions
How many clinical projects does SANGAMO THERAPEUTICS have?
1 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.